Camila I Amarista

Department of Internal Medicine, Division of Rheumatology, University of Michigan and Autoimmunity Center of Excellence, Ann Arbor, MI, USA.

2 publications 2022 – 2024
MiceAntibodies, MonoclonalAntigens, CDAntigens, Differentiation, T-LymphocyteAntigens, Neoplasm

What does Camila I Amarista research?

Dr. Amarista studies rheumatoid arthritis, a condition where the body's immune system mistakenly attacks its own joints, causing pain and swelling. She investigates a particular protein called CD13 that leaks into the bloodstream, which activates the B1 receptor on cells involved in inflammation. By understandings how this activation leads to arthritis, her team explores ways to block this receptor, potentially offering new treatment strategies that would reduce inflammation without interfering with the overall immune response.

Key findings

  • CD13 was found to cause inflammatory arthritis by activating the bradykinin receptor B1 on immune cells, leading to heightened inflammation in joint tissues.
  • The study reported that the B1R receptor is overactive in patients with rheumatoid arthritis, indicating it plays a critical role in the disease.
  • Blocking the B1R receptor with drugs successfully halted inflammation in human tissue samples and in mouse models, suggesting a promising therapeutic approach.

Frequently asked questions

Does Dr. Amarista study rheumatoid arthritis?
Yes, she specifically investigates the mechanisms that drive inflammation in rheumatoid arthritis and potential treatments.
What treatments has Dr. Amarista researched?
Her work explores blocking the bradykinin receptor B1 as a way to reduce inflammation in rheumatoid arthritis.
How might Dr. Amarista's research help patients?
Her research could lead to new treatments that effectively reduce joint inflammation in rheumatoid arthritis without compromising the overall immune response.

Publications in plain English

Activation of cytotoxic lymphocytes through CD6 enhances killing of cancer cells.

2024

Cancer immunology, immunotherapy : CII

Gurrea-Rubio M, Wu Q, Amin MA, Tsou PS, Campbell PL +14 more

Plain English
This study investigated how a special antibody, UMCD6, affects immune cells that fight cancer. Researchers found that UMCD6 helps these immune cells, particularly natural killer (NK) cells and certain T cells, become more effective at killing cancer cells in mice with breast and prostate cancer, leading to improved survival rates. Specifically, treated mice had more powerful immune cells that were better positioned to attack tumors compared to those treated with a standard antibody. Who this helps: This benefits cancer patients by potentially improving treatments that enhance their immune responses to tumors.

PubMed

Soluble CD13 induces inflammatory arthritis by activating the bradykinin receptor B1.

2022

The Journal of clinical investigation

Tsou PS, Lu C, Gurrea-Rubio M, Muraoka S, Campbell PL +26 more

Plain English
Researchers discovered that a protein called CD13, which leaks into the bloodstream, causes inflammatory arthritis by activating a receptor called B1R found on joint cells. They confirmed this by showing that blocking B1R with drugs stopped the inflammation in multiple types of arthritis in mice and in human joint tissue samples. This matters because B1R could be a new drug target to treat rheumatoid arthritis and other inflammatory diseases by preventing CD13 from triggering joint inflammation.

PubMed

Publication data sourced from PubMed . Plain-English summaries generated by AI. Not medical advice.